The once-daily tablet is the third approved treatment for fibrodysplasia ossificans progressiva (FOP), with CYP3A4 and metformin interaction guidance.
|Videos|October 5, 2016
Overcoming High Copays to Improve Drug Adherence
Author(s)Lauren Santye, Assistant Editor
Rebekah L. Hanson, PharmD, BCPS, BCACP, clinical pharmacist and assistant professor at the UIC College of Pharmacy, discusses the challenge of out-of-pocket spending and the impact on drug adherence.
Advertisement
Rebekah L. Hanson, PharmD, BCPS, BCACP, clinical pharmacist and assistant professor at the UIC College of Pharmacy, discusses the challenge of out-of-pocket spending and the impact on drug adherence.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Pharmacy Times
1
Ramantamig's 93.6% ORR and Outpatient CRS Control
2
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
3
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
4
Influenza Vaccines Continue to Reduce Severe Disease and Death Across High-Risk Groups, Evidence Review Finds
5